CN1158994C - 含环丙沙星和地塞米松的局部悬浮制剂 - Google Patents
含环丙沙星和地塞米松的局部悬浮制剂 Download PDFInfo
- Publication number
- CN1158994C CN1158994C CNB008132623A CN00813262A CN1158994C CN 1158994 C CN1158994 C CN 1158994C CN B008132623 A CNB008132623 A CN B008132623A CN 00813262 A CN00813262 A CN 00813262A CN 1158994 C CN1158994 C CN 1158994C
- Authority
- CN
- China
- Prior art keywords
- weight
- dexamethasone
- ciprofloxacin
- preparation
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 239000000725 suspension Substances 0.000 title claims abstract description 16
- 238000009472 formulation Methods 0.000 title abstract description 18
- NTRHYMXQWWPZDD-WKSAPEMMSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NTRHYMXQWWPZDD-WKSAPEMMSA-N 0.000 title description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 36
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 22
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract description 18
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 16
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 14
- 239000012744 reinforcing agent Substances 0.000 claims description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 10
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 10
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 10
- 229920000831 ionic polymer Polymers 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- -1 hydroxypropyl Chemical group 0.000 claims description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 8
- 239000004327 boric acid Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- 230000036571 hydration Effects 0.000 claims description 6
- 238000006703 hydration reaction Methods 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229940032912 zephiran Drugs 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- AKUJBENLRBOFTD-RPRRAYFGSA-N Dexamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-RPRRAYFGSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 235000004443 Ricinus communis Nutrition 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 2
- KCQUJORJVXQRST-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN KCQUJORJVXQRST-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 2
- 239000012929 tonicity agent Substances 0.000 abstract description 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 56
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 238000004062 sedimentation Methods 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000228245 Aspergillus niger Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
成分 | A%(w/w) | B%(w/w) | C%(w/w) | D%(w/w) | E%(w/w) |
一水合盐酸环丙沙星 | 0.35* | 0.35 | 0.35 | 0.35 | 0.35 |
地塞米松醇 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
羟乙基纤维素 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
氯苄烷铵 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
乙酸钠(三水合物) | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
乙酸 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
氯化钠 | 0.25 | 0.25 | 0.80 | 0.53 | --- |
乙二胺四乙酸二钠 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
四丁酚醛 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
甘油 | 1.5 | --- | --- | --- | 2.35 |
硼酸 | --- | --- | --- | 0.6 | --- |
NaOH/HCl | 适量pH4.5±0.2 | 适量pH4.5±0.2 | 适量pH4.5±0.2 | 适量pH4.5±0.2 | 适量pH4.5±0.2 |
纯水 | 适量100 | 适量100 | 适量100 | 适量100 | 适量100 |
重量摩尔渗透压浓度(mOsm) | 272 | 99 | 274 | 286 | 290 |
加速沉降 | 真实时间沉降 | |
制剂 | 再悬浮时间(秒) | 完全再悬浮的反转次数 |
A | 111211 | 171619 |
B* | 67 | 1616 |
C | 131619 | 121311 |
D | 796 | 121311 |
E | >60>60>60 | 182619 |
制剂 | |||||
试验有机体 | 时间 | A | B | C | D |
S.Aureus | 开始6小时24小时7天14天28天 | 6.05.05.05.05.05.0 | 6.15.15.15.15.15.1 | 6.15.15.15.15.15.1 | 5.94.94.94.94.94.9 |
P.Aeruginosa | 开始6小时24小时7天14天28天 | 6.05.05.05.05.05.0 | 6.05.05.05.05.05.0 | 6.05.04.75.05.05.0 | 6.05.05.05.05.05.0 |
E.Coli | 开始6小时24小时7天14天28天 | 6.04.04.04.04.04.0 | 6.04.04.04.04.04.0 | 6.04.04.04.04.04.0 | 5.93.93.93.93.93.9 |
C.Albicans | 开始7天14天28天 | 6.05.05.05.0 | 6.15.15.15.1 | 6.14.75.15.1 | 6.15.15.15.1 |
A.Niger | 开始7天14天28天 | 6.11.82.02.5 | 5.90.90.81.5 | 5.90.91.01.5 | 6.11.81.94.3 |
满足PET要求 | USP和Ph.Eur.B | 仅USP | USPPh.Eur.B | USPPh.Eur.B |
试验有机体 | 时间 | 初始值 | 52周的值 |
S.Aureus | 开始6小时24小时7天14天28天 | 6.05.05.05.05.05.0 | 6.05.05.05.05.05.0 |
P.Aeruginosa | 开始6小时24小时7天14天28天 | 6.05.05.05.05.05.0 | 6.15.05.05.05.05.0 |
E.Coli | 开始6小时24小时7天14天28天 | 6.04.04.04.04.04.0 | 6.04.04.04.04.04.0 |
C.Albicans | 开始7天14天28天 | 6.05.05.05.0 | 6.05.05.05.0 |
A.Niger | 开始7天14天28天 | 6.11.82.02.5 | 6.21.01.21.7 |
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15594299P | 1999-09-24 | 1999-09-24 | |
US60/155,942 | 1999-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1376054A CN1376054A (zh) | 2002-10-23 |
CN1158994C true CN1158994C (zh) | 2004-07-28 |
Family
ID=22557406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008132623A Expired - Lifetime CN1158994C (zh) | 1999-09-24 | 2000-08-10 | 含环丙沙星和地塞米松的局部悬浮制剂 |
Country Status (22)
Country | Link |
---|---|
US (2) | US6284804B1 (zh) |
EP (1) | EP1214056B1 (zh) |
JP (2) | JP2003510263A (zh) |
KR (1) | KR100722502B1 (zh) |
CN (1) | CN1158994C (zh) |
AR (1) | AR025661A1 (zh) |
AT (1) | ATE252887T1 (zh) |
AU (1) | AU776609B2 (zh) |
BR (1) | BR0014203A (zh) |
CA (1) | CA2379605C (zh) |
DE (1) | DE60006262T2 (zh) |
DK (1) | DK1214056T3 (zh) |
ES (1) | ES2207549T3 (zh) |
HK (1) | HK1045653B (zh) |
MX (1) | MXPA02003130A (zh) |
PL (1) | PL201130B1 (zh) |
PT (1) | PT1214056E (zh) |
SA (1) | SA00210418B1 (zh) |
TR (1) | TR200200737T2 (zh) |
TW (1) | TWI228423B (zh) |
WO (1) | WO2001022936A1 (zh) |
ZA (1) | ZA200201904B (zh) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2379605C (en) * | 1999-09-24 | 2007-06-26 | Alcon, Inc. | Topical suspension formulations containing ciprofloxacin and dexamethasone |
MXPA03004241A (es) * | 2000-11-15 | 2004-12-03 | Chandavarkar Mohan A | Preparaciones farmaceuticas que comprenden corticosteroides y agentes antiinfecciosos. |
CN1259049C (zh) * | 2001-07-06 | 2006-06-14 | 苏坎波公司 | 包含白介素-2抑制剂和抗菌剂的局部给药组合物 |
DK1429780T3 (da) * | 2001-09-21 | 2006-02-13 | Fremgangsmåde til behandling af mellemoreinfektioner | |
US20090215735A1 (en) * | 2002-02-25 | 2009-08-27 | Alcon, Inc. | Topical solution formulations containing a corticosteroid and a cyclodextrin |
EP2277522B1 (en) * | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
AU2003280960A1 (en) | 2002-07-15 | 2004-02-02 | Alcon, Inc. | Pharmaceutical compositions for otic use |
US20040101506A1 (en) * | 2002-11-25 | 2004-05-27 | Fust Charles A. | Composition for the prevention and treatment of inflammation of the ear |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
UY28126A1 (es) * | 2002-12-24 | 2004-06-30 | Alcon Inc | Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular |
EP1596823A2 (en) * | 2003-02-21 | 2005-11-23 | Sun Pharmaceuticals Industries Ltd. | A stable ophthalmic composition |
US20040202687A1 (en) * | 2003-04-14 | 2004-10-14 | Babu M.K. Manoj | Ciprofloxacin formulations and methods of making and using the same |
US20050085446A1 (en) * | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
WO2004103373A1 (ja) * | 2003-05-23 | 2004-12-02 | Santen Pharmaceutical Co.,Ltd. | キノロン系抗菌化合物を含有する点眼液 |
ES2552936T3 (es) | 2003-12-12 | 2015-12-03 | Otic Pharma Ltd. | Composiciones para el tratamiento del desordenes en el oído y métodos para el uso de los mismos |
US8940321B2 (en) * | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
ES2245611B1 (es) * | 2004-06-29 | 2007-03-16 | Laboratorio Reig Jofre, S.A. | Composicion farmaceutica para uso ototopico. |
US20060019987A1 (en) * | 2004-07-23 | 2006-01-26 | Fust Charles A | Methods and compositions for inhibiting, destroying, and/or inactivating viruses |
DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US7993675B2 (en) | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US7976873B2 (en) * | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
WO2008035246A2 (en) | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
US8088095B2 (en) * | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
CN101317847B (zh) * | 2007-06-06 | 2010-10-13 | 深圳市瑞谷医药技术有限公司 | 一种眼用或耳鼻用药物组合物及其用途 |
US8271101B2 (en) * | 2007-08-29 | 2012-09-18 | Advanced Bionics | Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead |
JP4696251B2 (ja) * | 2007-12-28 | 2011-06-08 | 防衛省技術研究本部長 | 多剤耐性緑膿菌の単離方法並びに多剤耐性緑膿菌選択培地の作成方法 |
CN101970042A (zh) * | 2008-02-25 | 2011-02-09 | 眼门药品公司 | 经由离子电渗法增强递送治疗药物至眼部组织 |
KR101534422B1 (ko) * | 2008-05-14 | 2015-07-09 | 오토노미, 인코포레이티드 | 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 |
WO2009152374A2 (en) | 2008-06-12 | 2009-12-17 | Medtronic Xomed, Inc. | Method for treating chronic wounds |
US20110117189A1 (en) * | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
US20100016450A1 (en) * | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
EP2346324A4 (en) | 2008-10-06 | 2012-10-10 | Microbial Defense Systems Llc | ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING |
TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
US20100226992A1 (en) * | 2009-03-03 | 2010-09-09 | Alcon Research, Ltd. | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye |
WO2010101989A1 (en) * | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
EP3508197A1 (en) * | 2009-10-21 | 2019-07-10 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
ES2391721T3 (es) | 2010-03-01 | 2012-11-29 | Laboratorios Salvat, S.A. | Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído |
US8916171B2 (en) | 2010-04-27 | 2014-12-23 | Topical Sinus Therapeutics, Inc. | Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis |
AU2012253476B2 (en) | 2011-05-10 | 2015-09-24 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
MX2014006803A (es) * | 2011-12-09 | 2014-07-09 | Lupin Ltd | Composiciones farmaceuticas topicas de agentes antimicrobianos y agentes antiinflamatorios. |
CN103565816A (zh) * | 2012-07-25 | 2014-02-12 | 天津金耀集团有限公司 | 妥布霉素地塞米松滴眼液 |
US9561240B2 (en) | 2012-12-26 | 2017-02-07 | Otic Pharma Ltd. | Foamable otic pharmaceutical compositions |
US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
EP3038707A4 (en) | 2013-08-27 | 2017-03-01 | Otonomy, Inc. | Treatment of pediatric otic disorders |
US20150119371A1 (en) * | 2013-10-30 | 2015-04-30 | Micro Labs Limited | Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents |
US9220796B1 (en) | 2014-07-03 | 2015-12-29 | Otonomy, Inc. | Sterilization of ciprofloxacin composition |
US9393243B1 (en) * | 2015-07-14 | 2016-07-19 | Nilesh Parikh | Topical Ciprofloxacin compositions |
KR20190109604A (ko) * | 2016-05-06 | 2019-09-25 | 해로우 헬스 인코포레이티드 | 약학적 안과용 조성물 및 그의 제조 방법 |
WO2018036819A1 (en) * | 2016-08-24 | 2018-03-01 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical formulation comprising a reconstituted pulmonary surfactant composition |
EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA |
CN107970244B (zh) * | 2016-10-21 | 2020-07-14 | 武汉武药科技有限公司 | 一种含有环丙沙星和地塞米松的组合物及其制备方法 |
CN108403700A (zh) * | 2018-06-12 | 2018-08-17 | 新疆生产建设兵团第师畜牧兽医工作站 | 一种牛呼吸道疾病治疗用复合注射液 |
JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤 |
CN113797163B (zh) * | 2020-06-17 | 2023-07-14 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂 |
CN113144207A (zh) * | 2021-02-07 | 2021-07-23 | 山西利普达医药科技有限公司 | 一种包括聚季铵盐-1的组合物及其应用 |
WO2024123098A1 (ko) * | 2022-12-09 | 2024-06-13 | 가톨릭대학교 산학협력단 | 내이 특이적 약물 전달용 조성물 및 이의 용도 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3134718A (en) | 1963-12-12 | 1964-05-26 | Schering Corp | Pregna-1,4-dienes and compositions containing same |
US4670444B1 (en) | 1980-09-03 | 1999-02-09 | Bayer Ag | and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds |
US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
US4686214A (en) | 1985-10-30 | 1987-08-11 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
DE3704907A1 (de) | 1987-02-17 | 1988-08-25 | Bayer Ag | Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden |
GB8805268D0 (en) * | 1988-03-04 | 1988-04-07 | Glaxo Group Ltd | Medicaments |
WO1990001933A1 (en) * | 1988-08-26 | 1990-03-08 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
ATE162081T1 (de) | 1991-09-17 | 1998-01-15 | Alcon Lab Inc | Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen |
ES2065846B1 (es) * | 1993-04-20 | 1995-10-01 | Cusi Lab | Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica. |
US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
JP3781792B2 (ja) * | 1993-12-27 | 2006-05-31 | 千寿製薬株式会社 | ジフルプレドナート含有点眼用懸濁液剤 |
ES2078175B1 (es) | 1993-12-31 | 1996-10-16 | Cusi Lab | Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. |
US5422116A (en) * | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US5843930A (en) | 1995-06-06 | 1998-12-01 | Bayer Corporation | Method of treating otitis with ciprofloxacin-hydrocortisone suspension |
DE19524691A1 (de) | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
KR0155950B1 (ko) | 1995-08-16 | 1998-12-01 | 김광호 | 플라즈마 확산 제어 방법 및 그 장치 |
KR100508227B1 (ko) | 1997-03-14 | 2006-03-23 | 센주 세이야꾸 가부시키가이샤 | 로테프레드놀에타보네이트수성현탁액 |
AR020661A1 (es) | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento |
AR020660A1 (es) | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | Composiciones antibioticas para el tratamiento de ojos, oidos y nariz |
US6395746B1 (en) | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
CA2344050A1 (en) | 1998-09-30 | 2000-04-06 | Alcon Laboratories, Inc. | Antibiotic compositions for treatment of the eye, ear and nose |
CA2379605C (en) * | 1999-09-24 | 2007-06-26 | Alcon, Inc. | Topical suspension formulations containing ciprofloxacin and dexamethasone |
-
2000
- 2000-08-10 CA CA002379605A patent/CA2379605C/en not_active Expired - Lifetime
- 2000-08-10 CN CNB008132623A patent/CN1158994C/zh not_active Expired - Lifetime
- 2000-08-10 AT AT00959213T patent/ATE252887T1/de active
- 2000-08-10 JP JP2001526148A patent/JP2003510263A/ja active Pending
- 2000-08-10 AU AU70570/00A patent/AU776609B2/en not_active Expired
- 2000-08-10 DE DE60006262T patent/DE60006262T2/de not_active Expired - Lifetime
- 2000-08-10 TR TR2002/00737T patent/TR200200737T2/xx unknown
- 2000-08-10 PL PL359623A patent/PL201130B1/pl unknown
- 2000-08-10 BR BR0014203-4A patent/BR0014203A/pt not_active Application Discontinuation
- 2000-08-10 US US09/636,563 patent/US6284804B1/en not_active Expired - Lifetime
- 2000-08-10 DK DK00959213T patent/DK1214056T3/da active
- 2000-08-10 EP EP00959213A patent/EP1214056B1/en not_active Expired - Lifetime
- 2000-08-10 WO PCT/US2000/021961 patent/WO2001022936A1/en active IP Right Grant
- 2000-08-10 MX MXPA02003130A patent/MXPA02003130A/es active IP Right Grant
- 2000-08-10 PT PT00959213T patent/PT1214056E/pt unknown
- 2000-08-10 KR KR1020027003205A patent/KR100722502B1/ko active IP Right Grant
- 2000-08-10 ES ES00959213T patent/ES2207549T3/es not_active Expired - Lifetime
- 2000-08-28 TW TW089117377A patent/TWI228423B/zh not_active IP Right Cessation
- 2000-09-14 AR ARP000104822A patent/AR025661A1/es unknown
- 2000-10-03 SA SA00210418A patent/SA00210418B1/ar unknown
-
2001
- 2001-05-25 US US09/865,783 patent/US6359016B2/en not_active Expired - Lifetime
-
2002
- 2002-03-07 ZA ZA200201904A patent/ZA200201904B/en unknown
- 2002-09-27 HK HK02107186.7A patent/HK1045653B/zh not_active IP Right Cessation
-
2010
- 2010-11-18 JP JP2010258386A patent/JP2011032293A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20020069508A (ko) | 2002-09-04 |
CA2379605C (en) | 2007-06-26 |
WO2001022936A8 (en) | 2002-01-24 |
AU776609B2 (en) | 2004-09-16 |
DE60006262T2 (de) | 2004-05-13 |
CA2379605A1 (en) | 2001-04-05 |
JP2003510263A (ja) | 2003-03-18 |
ZA200201904B (en) | 2003-05-28 |
BR0014203A (pt) | 2002-05-21 |
AU7057000A (en) | 2001-04-30 |
US20010034339A1 (en) | 2001-10-25 |
HK1045653B (zh) | 2004-01-30 |
MXPA02003130A (es) | 2004-04-21 |
DE60006262D1 (de) | 2003-12-04 |
JP2011032293A (ja) | 2011-02-17 |
EP1214056A1 (en) | 2002-06-19 |
SA00210418B1 (ar) | 2006-04-22 |
US6284804B1 (en) | 2001-09-04 |
US6359016B2 (en) | 2002-03-19 |
PL201130B1 (pl) | 2009-03-31 |
ATE252887T1 (de) | 2003-11-15 |
TWI228423B (en) | 2005-03-01 |
PT1214056E (pt) | 2004-02-27 |
HK1045653A1 (en) | 2002-12-06 |
KR100722502B1 (ko) | 2007-05-28 |
WO2001022936A1 (en) | 2001-04-05 |
DK1214056T3 (da) | 2004-02-09 |
EP1214056B1 (en) | 2003-10-29 |
CN1376054A (zh) | 2002-10-23 |
PL359623A1 (en) | 2004-08-23 |
ES2207549T3 (es) | 2004-06-01 |
AR025661A1 (es) | 2002-12-11 |
TR200200737T2 (tr) | 2002-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1158994C (zh) | 含环丙沙星和地塞米松的局部悬浮制剂 | |
CN1211125C (zh) | 局部给药的盐酸奥洛他定制剂 | |
JP5538464B2 (ja) | テルペノイドを含有するソフトコンタクトレンズ用眼科組成物 | |
CN1762381B (zh) | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 | |
JP2018188440A5 (zh) | ||
CN1282256A (zh) | 药物悬浮液的新型灭菌法 | |
JPH06501258A (ja) | 非水性のパーフルオロ化担体中に懸濁したドラッグデリバリー賦形剤 | |
EP2653155A1 (en) | Ophthalmic composition for contact lens | |
CN101199855A (zh) | 皮质激素包合物水溶液及其应用 | |
HU213511B (en) | Process for producing pharmaceutical composition containing megestrol acetate | |
HUE025838T2 (en) | Nanoparticulate suspensions containing carboxyvinyl polymer | |
JP2004531569A (ja) | ピレンゼピン眼科用ゲル剤 | |
US20150165051A1 (en) | Aqueous ophthalmic composition | |
CN100366256C (zh) | 含有环索奈德的无菌水性混悬剂 | |
JP2010265261A (ja) | レボカバスチン懸濁型点眼剤 | |
KR20100129263A (ko) | 다당류 미립자상 겔 함유 수분산체 및 그 제조 방법 | |
CN1063944C (zh) | 眼用复方妥布霉素混悬液的制法 | |
JP5794977B2 (ja) | アニオン性治療剤を含む水性眼用組成物 | |
US20090081135A1 (en) | Iodine-based oral antibacterial treatment methodology | |
CN1846710A (zh) | 一种女性阴道清洗剂 | |
JPS6067468A (ja) | 新規な注射用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191218 Address after: Basel Patentee after: Novartis Co., Ltd. Address before: Hananberg, Switzerland Patentee before: Alcon Company |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191223 Address after: Fribourg Patentee after: Alcon Company Address before: Basel Patentee before: Novartis Co., Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20040728 |